PerkinElmer enhances Hand Sanitizer Analyzer to detect methanol in 30 seconds
The instrument also tests ethanol and isopropanol concentrations to confirm product efficacy.
PerkinElmer has announced that its Hand Sanitizer Analyzer instrument can be used to test for the presence of methanol in alcohol-based hand sanitizer products with pass/fail results delivered in 30 seconds or less.
Recent warnings and recalls from the FDA indicate that methanol can be toxic to consumers if absorbed through the skin and life threatening if ingested.
The instrument, brought to market in April 2020, also tests hand sanitizers for concentration levels of desired alcohols, such as ethanol and isopropanol, to help assure product efficacy per WHO, USP or FDA guidelines.
The compact and portable analyser is based on the company’s Spectrum Two FT-IR spectrometer solution and can rapidly detect methanol contamination down to 0.03% (or 300 parts per million), which is more sensitive than the FDA mandated detection limits.
“With the COVID-19 pandemic continuing and the flu season on its way, it is critical that consumers can trust the safety and efficacy of alcohol-based hand sanitizer products,” said Suneet Chadha, VP/GM, Applied Markets, PerkinElmer. “Our PerkinElmer Hand Sanitizer Analyzer puts fast and reliable results into the hands of the producers and suppliers of these high-demand products, protecting consumers and avoiding counterfeit ingredient use and recalls.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance